BMO Capital Markets lowered shares of Eli Lilly and Co. (NYSE:LLY) from an outperform rating to a market perform rating in a research report report published on Wednesday.

LLY has been the subject of a number of other research reports. Jefferies Group reissued a buy rating and issued a $100.00 price objective (down previously from $105.00) on shares of Eli Lilly and in a research report on Friday, October 28th. Citigroup Inc. reissued a buy rating on shares of Eli Lilly and in a research report on Tuesday, November 8th. JPMorgan Chase & Co. raised shares of Eli Lilly and from a neutral rating to an overweight rating and boosted their price objective for the company from $92.00 to $95.00 in a research report on Thursday, September 8th. Leerink Swann reissued a buy rating and issued a $103.00 price objective on shares of Eli Lilly and in a research report on Sunday, October 9th. Finally, Zacks Investment Research lowered shares of Eli Lilly and from a buy rating to a hold rating in a research report on Wednesday, October 5th. Three investment analysts have rated the stock with a hold rating and eighteen have issued a buy rating to the company’s stock. The company has an average rating of Buy and a consensus price target of $95.39.

Shares of Eli Lilly and (NYSE:LLY) traded down 10.51% during trading on Wednesday, reaching $68.00. The company had a trading volume of 53,975,853 shares. The company’s 50 day moving average is $77.17 and its 200-day moving average is $77.97. The stock has a market capitalization of $71.92 billion, a price-to-earnings ratio of 29.58 and a beta of 0.28. Eli Lilly and has a 1-year low of $64.18 and a 1-year high of $88.16.

Eli Lilly and (NYSE:LLY) last posted its quarterly earnings data on Tuesday, October 25th. The company reported $0.88 earnings per share for the quarter, missing analysts’ consensus estimates of $0.96 by $0.08. The firm earned $5.19 billion during the quarter, compared to analyst estimates of $4.23 billion. Eli Lilly and had a net margin of 11.73% and a return on equity of 23.71%. The business’s quarterly revenue was up 4.7% on a year-over-year basis. During the same period in the prior year, the firm earned $0.89 EPS. On average, equities research analysts anticipate that Eli Lilly and will post $3.55 earnings per share for the current year.

The company also recently announced a quarterly dividend, which will be paid on Friday, December 9th. Shareholders of record on Tuesday, November 15th will be issued a $0.51 dividend. This represents a $2.04 annualized dividend and a dividend yield of 3.00%. The ex-dividend date of this dividend is Thursday, November 10th. Eli Lilly and’s payout ratio is 88.70%.

In other Eli Lilly and news, insider Maria A. Crowe sold 2,248 shares of the firm’s stock in a transaction dated Wednesday, October 5th. The shares were sold at an average price of $81.37, for a total value of $182,919.76. Following the completion of the transaction, the insider now directly owns 94,319 shares in the company, valued at $7,674,737.03. The sale was disclosed in a filing with the SEC, which is accessible through this link. 0.20% of the stock is currently owned by company insiders.

Hedge funds have recently bought and sold shares of the company. Iowa State Bank bought a new stake in Eli Lilly and during the second quarter worth about $104,000. PineBridge Investments L.P. raised its stake in Eli Lilly and by 208.6% in the second quarter. PineBridge Investments L.P. now owns 1,361 shares of the company’s stock worth $108,000 after buying an additional 920 shares during the period. Tradewinds Capital Management LLC raised its stake in Eli Lilly and by 22.3% in the third quarter. Tradewinds Capital Management LLC now owns 1,345 shares of the company’s stock worth $108,000 after buying an additional 245 shares during the period. Integrated Wealth Management raised its stake in Eli Lilly and by 3.7% in the third quarter. Integrated Wealth Management now owns 1,389 shares of the company’s stock worth $112,000 after buying an additional 50 shares during the period. Finally, Financial Architects Inc raised its stake in Eli Lilly and by 4.5% in the third quarter. Financial Architects Inc now owns 1,423 shares of the company’s stock worth $114,000 after buying an additional 61 shares during the period. 75.11% of the stock is owned by institutional investors and hedge funds.

ILLEGAL ACTIVITY WARNING: This report was first posted by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this report on another site, it was copied illegally and reposted in violation of U.S. and international copyright & trademark legislation. The correct version of this report can be read at https://www.thecerbatgem.com/2016/11/24/eli-lilly-and-co-lly-lowered-to-market-perform-at-bmo-capital-markets.html.

Eli Lilly and Company Profile

Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists.

5 Day Chart for NYSE:LLY

Receive News & Stock Ratings for Eli Lilly and Co. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and Co. and related stocks with our FREE daily email newsletter.